Association of adiponectin levels and insulin demand in critically ill patients

Diabetes, Metabolic Syndrome and Obesity

Volumn 4, Issue , 2011, Pages 45-51

  Hillenbrand, Andreas ^a   Weiss, Manfred ^a   Knippschild, Uwe ^a   Stromeyer, Hans G ^a   Henne Bruns, Doris ^a   Huber Lang, Markus ^a   Wolf, Anna M ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Adipokines; Diabetes; Leptin; Resistin; Sepsis

Indexed keywords

ADIPONECTIN; ADRENALIN; HYDROCORTISONE; INSULIN; LEPTIN; RESISTIN; SUGAR;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MALE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; SEPTIC SHOCK; SEX DIFFERENCE;

EID: 79953079750     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S15211     Document Type: Article

References (28)

1. Langouche L, van den Berghe G. Glucose metabolism and insulin therapy. Crit Care Clin. 2006;22(1):119-129.
2. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354(5):449-461.
3. Fritsche L, Weigert C, Häring HU, Lehmann R. How insulin receptor substrate proteins regulate the metabolic capacity of the liver - implications for health and disease. Curr Med Chem. 2008;15(13): 1316-1329.
4. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14(11-12):741-751.
5. Ouchi N, Kihara S, Funahashi T, et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107(5):671-674.
6. Dyck DJ. Adipokines as regulators of muscle metabolism and insulin sensitivity. Appl Physiol Nutr Metab. 2009;34(3):396-402.
7. Hillenbrand A, Knippschild U, Weiss M, et al. Sepsis induced changes of adipokines and cytokines - septic patients compared to morbidly obese patients. BMC Surg. 2010;10(1):26.
8. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adiposespecific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
9. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302(2):179-188.
10. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101(6):1644-1655.
11. Le Gall JR, Lemeshow S, Saulnier F. A New Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957-2963.
12. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2:81-84.
13. Janssens U, Dujardin R, Graf J, et al. Value of SOFA (Sequential Organ Failure Assessment) score and total maximum SOFA score in 812 patients with acute cardiovascular disorders. Critical Care. 2001; 5(suppl 1):P225x.
14. Matsuzawa Y. Adiponectin: identification, physiology and clinical relevance in metabolic and vascular disease. Atheroscler Suppl. 2005; 6(2):7-14.
15. Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res. 2005;96(10): 1042-1052.
16. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 2007;56(8):2174-2177.
17. Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30(7): 1709-1716.
18. Verspohl EJ. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009;124(1):113-138.
19. Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001;86(10): 5083-5086.
20. Nakahara K, Okame R, Katayama T, Miyazato M, Kangawa K, Murakami N. Nutritional and environmental factors affecting plasma ghrelin and leptin levels in rats. J Endocrinol. 2010;207(1): 95-103.
21. Van den Hoek AM, Heijboer AC, Voshol PJ, et al. Chronic PYY3-36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab. 2007;292(1): E238-E245.
22. Billyard T, McTernan P, Kumar S. Potential therapies based on antidiabetic peptides. Best Pract Res Clin Endocrinol Metab. 2007;21(4): 641-655.
23. Lehrke M, Broedl UC, Biller-Friedmann IM, et al. Serum concentrations of cortisol, interleukin 6, leptin and adiponectin predict stress induced insulin resistance in acute inflammatory reactions. Crit Care. 2008; 12(6):R157.
24. Nagaev I, Bokarewa M, Tarkowski A, Smith U. Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS ONE 1. 2006:e31.
25. Pang SS, Le YY. Role of resistin in inflammation and inflammationrelated diseases. Cell Mol Immunol. 2006;3(1):29-34.
26. Steppan CM, Lazar MA. Resistin and obesity-associated insulin resistance. Trends Endocrinol Metab. 2002;13(1):18-23.
27. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010; 314(1):1-16.
28. Cook JR, Semple RK. Hypoadiponectinemia - cause or consequence of human "insulin resistance"? J Clin Endocrinol Metab. 2010;95(4): 1544-1554.